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The protein p300 is a multifunctional transcriptional coactivator that plays pivotal role in several
cellular functions. Although structures of several domains have been solved in isolation, the struc-
tures of full-length protein (p300 FL) or its complexes with transcription activators are completely
unknown. Herein, we applied atomic force microscopy to visualize p300 FL. We found that it is
almost prolate ellipsoidal in shape, having several bulges. We further identiﬁed the functionally sig-
niﬁcant N-terminal and C-terminal regions, by applying domain-speciﬁc antibodies and found that
they are located near one end and centre of the molecule, respectively. Importantly, we have visu-
alized the complex between p300 FL and tumor suppressor protein p53. The relevance of these data
in understanding dynamics of p300 during acetylation and transcription will be mentioned.
Structured summary of protein interactions:
p300 and p53 bind by atomic force microscopy (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The p300 protein is a transcriptional coactivator [1], which
plays a key role in cellular processes like proliferation, cell-cycle
regulation, apoptosis, differentiation and DNA damage response
[2,3]. The p300 possesses intrinsic histone acetyltransferase
(HAT) activity which modiﬁes chromatin during transcription
and other DNA template phenomenon [4,5]. Being a transcriptional
coactivator, it interacts with a large number of transcription factors
and RNA polymerase II transcription machinery [2,6]. Despite its
central role in gene expression, the crystal structure of p300 FL
has not been reported yet. Recently, the cocrystal structure of
p300 HAT domain with its speciﬁc, synthetic inhibitor Lys-CoA
has been determined [7], and the limited trypsin proteolysis and
SERS spectral analysis of p300 FL have provided some information
on overall domain organization [7,8]. In this work, we have ob-
tained information for the ﬁrst time on the tertiary structure of
p300 FL by applying AFM, which is a high-resolution local probe
imaging method for obtaining information on single biomolecules
[9]. AFM can provide direct 3D information on biomolecules of any
size. Therefore, in absence of a crystal structure and due to thechemical Societies. Published by E
ay).large size (300 kD) of p300 FL, AFM could be an attractive strategy
to exploit.
There are several domains in p300 that bind transcription fac-
tors and one of the most well-studied transcription factors that re-
cruits p300 is p53. The p53 binds DNA as a tetramer [10] and it has
been shown that phosphorylation of p53 enhances its afﬁnity to-
wards several p300 domains distributed throughout the structure
[11]. It has been suggested that all four molecules of p53 in a tet-
ramer interact with p300 during complex formation, presumably
with different domains [12]. However, no conclusive proof has
been offered yet. This complexity suggests that in absence of atom-
ically resolved structure of p300 FL, even molecular level resolu-
tion could shed light on the function of this important molecule.
In this study, apart from visualizing the p300 FL protein, we have
performed experiments to identify the location of the functionally
important C-terminal and N-terminal regions of p300 FL and to ob-
tain an idea about the domain structure. Moreover, we have lo-
cated the position of binding of p53 onto p300 FL by using a p53
mutant which contains a point mutation by glutamic acid at thre-
onine 18. We chose this particular mutant, since it is reported that
glutamic acid mimics phosphorylated threonine residue [13] and
phosphorylated threonine 18 of p53 binds most tightly with
p300 [11]. There are some reports [12,14] where p53 binding to
p300 is investigated using speciﬁc domains of either p300 orlsevier B.V. All rights reserved.
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protein molecules instead of the domains.1 The radius of curvature of the probe used was less than 10 nm which is small
enough for imaging of protein molecules. Given the present situation of imaging p300
FL, which is quite a large protein, the probe employed in our study is expected to
behave as a sufﬁciently sharp probe.2. Materials and methods
2.1. p300 FL puriﬁcation
p300 FL was puriﬁed from recombinant baculovirus-infected
Sf21 cells as a His6-tagged protein through nickel-nitrilotriacetic
acid afﬁnity column (Qiagen) as described previously [8].
2.2. Preparation of p300 FL solution
The p300 FL solution was freshly prepared in 10 mM Tris, 10%
glycerol, 200 mM NaCl, 50 ll protease inhibitor cocktail (0.1%
NP40, 2 mM b-ME, 2 mM PMSF, 50 lg/ml aprotinin, 50 lg/ml leu-
peptin) at pH 7.5 prior to each experiment.
2.3. Preparation of His-Tag mAb, IgG-AP, C-terminal speciﬁc antibody
and N-terminal speciﬁc antibody solutions
The respective stock solution was suitably diluted with an
appropriate buffer immediately before use. (See Supplementary
materials) for details.
2.4. Preparation of p53 mutant (T18E)
Site-directed mutagenesis was performed using wild type ﬂag
tagged p53 plasmid by PCR-based site-directed mutagenesis kit
(Agilent Technologies). Sequencing by dideoxy method showed
that desired mutation was incorporated within the plasmid.
Details of protein expression and puriﬁcation are provided in
Supplementary materials.
2.5. Preparation of p300 FL-antibody and p300 FL-p53 mutant
complexes
In order to form p300-antibody complexes, 0.4 ll p300 (10 nM)
and 0.6 ll antibody solutions (4.8 lg/ml His-Tag mAb or 4.0 lg/ml
IgG-AP/C-terminal speciﬁc antibody/N-terminal speciﬁc antibody)
were mixed and incubated at 37 C for 10 min in dark. For p300
FL–p53 complex formation, 2 ll of each of 10 nM p300 FL and
10 nM p53 mutant solutions were taken. Complex formation reac-
tion was carried out in a buffer containing 25 mM Tris–HCl,
150 mM NaCl, 20 lM ZnCl2, 2.5 mM b-ME and 10% glycerol of pH
7.5 at 27 C for 15 min in dark.
2.6. AFM sample preparation for imaging p300 FL
0.5 ll of 5 nM p300 solution was deposited onto freshly cleaved
muscovite mica (ICR & Sons Pvt. Ltd., India), kept for 15 min, fol-
lowed by gentle wash with 2 ml (250 ll  8) Milli-Q water, and
dried using gentle stream of nitrogen gas.
For in situ (i.e., inﬂuid) imagingofp300FL, gold(111)onmica sub-
strate (Phasis, Switzerland) was cleaned by ﬂame-annealing and
immersed into 0.5 mM ethanolic solution of 3-mercaptopropionic
acid (3-MPA) for 1 h followed by washing with 2 ml (500 ll  4)
ﬁltered ethanol and 2 ml (500 ll  4) Milli-Q water, and drying
with a stream of nitrogen gas. Then 3-MPA modiﬁed gold substrate
was immersed into freshly prepared aqueous solution of 75 mM
1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride
(EDC) and 15 mM N-hydroxysuccinimide (NHS), kept for 30 min,
followed by washing with 2 ml (500 ll  4) Milli-Q water. Then
the 3-MPA, NHS, EDC modiﬁed gold substrate was dried with a
stream of nitrogen gas. The p300 solution (50 pM) was depositedonto modiﬁed gold substrate and incubated for 10 min. The sample
surface was gently washed with 2 ml (250 ll  8) Milli-Q water.
2.7. AFM sample preparation for imaging p300 FL-antibody and p300
FL-p53 mutant complexes
1.0 ll of the p300 FL – antibody complex or the p300 FL – p53
mutant complex solution was deposited onto freshly cleaved mica
and kept for 15 min, then washed with 2 ml (250 ll  8) Milli-Q
water and dried using gentle stream of nitrogen gas.
2.8. AFM data acquisition and analysis
AFM imaging was performed using PicoLE AFM equipment
(Agilent Corp., USA) with 10  10 lm scanner at room temperature
(24 ± 1.0 C) in the intermittent contact mode (acoustic alternating
current or AAC mode). Standard rectangular silicon cantilevers
(lmasch, Estonia) of force constant 3.5–27.5 N/m were used for
ambient (i.e., in air) imaging. The cantilever oscillation frequency
was 171–202 kHz. For in situ imaging, SNL-10 cantilevers (Veeco)
of force constant 0.24 N/m were used. The cantilever oscillation
frequency was 40–75 kHz. The probes were cleaned in a UV-ozone
cleaner (Bioforce, Nanosciences) before imaging. Amplitude set
point was 85–90% of the free oscillation amplitude (7.5–8.0 V
in ambient and 4.0–6.0 V in ﬂuid). Scan speed was 0.5–2.0
lines/s. Standard data analysis procedures were adopted (see
Supplementary materials).
3. Results and discussion
In this work, we applied high-resolution AFM to visualize p300
FL molecules in situ (i.e., in ﬂuid) and in ambient (i.e., in air) condi-
tion. In order to identify the location of C-terminal, we employed a
His-Tag speciﬁc monoclonal antibody (His-Tag mAb) that can bind
to a His-Tag unit present at the C-terminal region of p300 FL, sec-
ond, a secondary antibody molecule IgG-AP that can bind speciﬁ-
cally to the primary antibody His-Tag mAb, and ﬁnally a C-
terminal speciﬁc antibody. For identifying the N-terminal of p300
FL, N-terminal speciﬁc antibody molecule was applied. Binding of
the tumor suppressor protein p53 to p300 FL was investigated
using the p53 mutant T18E. AFM imaging experiments were car-
ried out in intermittent contact mode to minimize tip-induced
damage of the soft protein exterior.
3.1. Topographic features of p300 FL
The in situ AFM 3D views of individual p300 FL molecules of
ellipsoidal shape with a distinct terminal bulge are shown in
Fig. 1. Similar molecular shape could be frequently detected also
in ambient condition. The average length of p300 FL molecules
was estimated to be 141.6 ± 15.2 nm (from in situ measurements)
and 141.2 ± 5.4 nm (from ambient measurements)1. While in all
the cases the terminal bulge was clearly visible, greater resolution,
as shown in Fig. 2(a), could be obtained in a few cases. Almost pro-
late ellipsoidal in shape, these molecules revealed presence of appar-
ently three smaller bulges and one small side-protrusion (Fig. 2(b))
apart from the big bulge at one end. It is evident in the cross-section
(Fig. 2(c)) that the terminal bulge is considerably bigger compared to
the other bulges. The smoothness of the cross-section proﬁle taken
across the bulge (Fig. 2(d)) indicates that this bulge is condense
and probably represents one single structural domain. In control
Fig. 1. In situ AFM topographic images (3D views) of covalently immobilized p300 molecules on NHS–EDC modiﬁed gold(111) surface (X, Y axes in nm and Z axis in Å).
Imaging was carried out in a buffer solution [10 mM Tris, 200 mM NaCl, 1 mM dithiothreitol (DTT), 2 mM phenylmethylsulfonylﬂuoride (PMSF) at pH 7.5]. The terminal bulge
is highlighted with arrow mark.
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Fig. 2. (a) AFM topograph of p300 FL molecules (marked by arrows) on mica surface in ambient condition, Z-range: 0–11.2 nm; (b) magniﬁed 3D view of one p300 molecule
(X, Y axes in nm and Z axis in Å); (c) cross-section along long axis and (d) cross-section across the big condense bulge. The 3D view in (b) reveals presence of apparently four
bulges (shown by short arrows) in the main body of the protein, and a protrusion (shown by long arrow).
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Supplementary material). It has been shown earlier that when low
concentration of the proteins are applied and the protein molecules
are adsorbed in single isolated condition, the proteins of non-spher-
ical shapes tend to adsorb having their long axes parallel to the sur-
face [15,16]. Precisely this has been the observation in case of p300
FL adsorption in each of our experiments leading to reproducible
observation of the ellipsoidal shape of p300 FL.
For visualization of the p300 FL in ambient condition, the p300
molecules were adsorbed on bare mica surface. But for imaging in
ﬂuid, the p300 molecules had to be covalently anchored on the sur-
face so that they were not desorbed from surface and get attached
to the AFM tip resulting in imaging difﬁculties. The covalent
anchoring of the full-length p300 molecules was achieved on 3-
MPA modiﬁed gold(111) surface with the help of NHS, EDC, where
the lysine residues at the protein surface could form covalent
amide links with the carboxylic end of 3-MPA [17]. In this case,
the protein molecule is not directly exposed to the surface but it
sits on a layer of 3-MPA. For both the situations, i.e., on bare mica
surface and on the 3-MPA modiﬁed gold(111) surface, the dimen-
sion, shape and the major structural features of full-length p300
molecule remained same indicating that in both the cases, the mol-
ecule sit on the surface in similar fashion and that there was no
major detrimental effect of direct adsorption on the molecular
structure of p300. Earlier in several studies using AFM and STM
(scanning tunneling microscopy), reasonable level of similarities
between the X-ray/NMR structure of a protein molecule and its
AFM/STM image characteristics was shown [18,19]. This indicatesthat the gross structural features are maintained on surface if the
protein molecules are carefully immobilized.
3.2. The C-terminal and the N-terminal of p300 FL are located at the
centre and at the terminal bulge position, respectively
In order to obtain further structural information on p300 FL, a
His-Tag speciﬁc monoclonal antibody (His-Tag mAb) that can bind
to a His-Tag unit introduced at the C-terminal region of p300 FL
was employed. The complexes appeared mostly ellipsoidal in
shape and about 151.6 ± 12.5 nm in length (Fig. 3(a)). In order to
conﬁrm the position of binding of His-Tag mAb to p300 FL, a sec-
ondary antibody molecule IgG-AP that would bind speciﬁcally to
the primary antibody His-Tag mAb, was also employed [20]. The
ternary complex (p300 FL– His-Tag mAb – IgG-AP) as shown in
Fig. 3(b) was about 151.3 ± 13.0 nm in length. Further evidence
for identiﬁcation of the C-terminal region of p300 FL was still
sought after since there was a possibility that His-Tag mAb could
bind at a location near C-terminal and not precisely at C-terminal
due to dangling disposition of His-Tag around its attachment point.
We therefore applied a p300 FL C-terminal speciﬁc antibody for ex-
plicit identiﬁcation of the C-terminal location. The complexes be-
tween p300 FL and this antibody were elongated in shape
(Fig. 3(c)), having an average length of 151.1 ± 12.6 nm. Lastly, as
a natural query whether the N-terminal region could also be de-
tected, a p300 FL N-terminal speciﬁc antibody was employed. From
the AFM topographs of p300 FL – p300 FL N-terminal speciﬁc anti-
body complex, it is evident that this antibody binds at a completely
50 nm 
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(b) 
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Fig. 3. AFM topographic images of the complex (a) p300 FL - His-Tag mAb, (b) p300
FL - His-Tag mAb – IgG-AP, (c) p300 FL – p300 FL C-terminal speciﬁc antibody, (d)
p300 FL – p300 FL N-terminal speciﬁc antibody, (e) p300 FL – p53 mutant (T18E). Z-
range: (a) 0–11.0 nm, (b) 0–15.5 nm, (c) 0–12.5 nm and (d) 0–13.0 nm, (e) 0–
12.0 nm.
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Fig. 4. Complexes formed between p300 FL and different antibody molecules. From
left, are shown 3D views (X, Y axes in nm and Z axis in Å) and schematic drawings of
the complexes along with a dotted line drawn along the contour of schematic as a
representation of the path of the AFM tip, and cross-sections along the long axes of
the complexes. Along the rows, are shown (a) p300 FL, (b) p300 FL – His-Tag mAb
complex (blue ball indicates antibody positioning), (c) p300 FL – His-Tag mAb –
IgG-AP complex (blue ball and pink ball indicates His-Tag mAb and IgG-AP,
respectively), (d) p300 FL – p300 FL C-terminal speciﬁc antibody complex (the
brown ball indicates antibody positioning), (e) p300 FL – p300 FL N-terminal
speciﬁc antibody complex (green ball indicates antibody positioning), (f) p300 FL –
p53 mutant (T18E) complex (dark blue ball indicates p53 positioning). For the
representative image galleries and the cross-section galleries, see Supplementary
material.
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mAb/C-terminal speciﬁc antibody binding (Fig. 3(d)). The average
length of these complexes was estimated as 151.2 ± 13.4 nm. All
the antibody molecules were characterized by AFM prior to com-
plex formation step (see Supplementary material). The antibodies
looked spherical in shape, and were of sizes 35.1 ± 8.3 nm (His-Tag
mAb), 38.5 ± 9.9 nm (IgG-AP), 39.8 ± 13.4 nm (C-terminal speciﬁc
antibody) and 38.5 ± 8.7 nm (N-terminal speciﬁc antibody).
While one large terminal hump and two small humps were ob-
served in the cross-section proﬁle of p300 FL (Fig. 4(a)), a smooth
cross-section was observed in case of p300 FL–His-tag mAb com-
plex (Fig. 4(b)). Observation of such a cross-section is possible only
if the antibody binds at the central region of p300 FL, as depicted in
the schematic diagram in Fig. 4(b). A dotted line proﬁle, represent-
ing the path of the AFM tip, can be drawn along the contour of the
schematic diagram. Here we consider the fact that the AFM tip is
not sharp enough to resolve small curvatures on the protein con-
tour. A close similarity between this dotted line proﬁle and the
cross-section along the long axis of the complex could be observed,
indicating that the schematic diagram represents the p300 FL–
antibody complex architecture reasonably well. The relativelygreater height value of the complex compared to p300 FL (Table 1)
is compatible with binding of the antibody molecule and earlier re-
Table 1
Comparison between height and length values of p300 FL and p300 FL-antibody/p53 complexes.
Molecule/complex Height (nm) Length (nm)
Free p300 FL 3.3 ± 0.1 (central region) 141.6 ± 15.2 (in situ condition)
6.4 ± 0.6 (terminal bulge) 141.2 ± 5.4 (ambient condition)
p300 FL – His-Tag mAb 10.2 ± 0.9 151.6 ± 12.5
p300 FL – His-Tag mAb – IgG-AP 13.5 ± 2.5 151.3 ± 13.0
p300 FL – p300 FL C-terminal speciﬁc antibody 11.6 ± 1.7 151.1 ± 12.6
p300 FL – p300 FL N-terminal speciﬁc antibody 9.6 ± 2.0 151.2 ± 13.4
p300 FL – p53 mutant (T18E) 11.3 ± 1.2 129.5 ± 9.2
3 Though it is really interesting to correlate the height values with the binding of
monomeric, dimeric or tetrameric p53, it could be oversimpliﬁed in our situation. The
molecular weight of an antibody molecule is 150 kD and the monomeric p53 should
have a molecular weight of 53 kD. We found that the total height value of p300 FL –
His-Tag mAb complex and p300 FL – p300 FL C-terminal speciﬁc antibody complex
(where one antibody molecule is bound at the central region of p300) is close to the
height value of p300 FL – p53 complex where p53 is bound at the central portion of
S. Banerjee et al. / FEBS Letters 586 (2012) 3793–3798 3797ports that antibody binding to an antigen can be elicited from AFM
height value increase [21]. The p300 FL – His-Tag mAb – IgG-AP
complex clearly revealed a symmetric disposition (see cross-
section in Fig. 4(c)) quite like that for the p300 FL – His-Tag mAb
complex (Fig. 4(b)), except for a protruded central region and a
greater height value (Table 1). Formation of such a contour is pos-
sible only if the secondary antibody molecule binds on top of the
primary antibody molecule (see the schematic diagram in
Fig. 4(c)). These ﬁndings support the fact that the primary antibody
binds to the central region of p300 FL, and therefore the C-terminal
is located at the central region of p300 FL. Further conﬁrmatory
evidence in support of this proposition could be found from the
observation of an almost symmetric cross-section proﬁle of the
p300 FL – C-terminal speciﬁc antibody complex (Fig. 4(d)). It is
clearly indicated in the cross-section that the antibody binds at
the central region of p300 FL. The greater height value of the
complex compared to that of the free p300 FL (Table 1) also
corresponds well with antibody binding. These observations
(Figs. 4(a)–(d)) therefore collectively conﬁrm that the C-terminal
of p300 FL is centrally located.
In case of the p300 FL – N-terminal speciﬁc antibody complex,
the cross-section proﬁle was asymmetric (Fig. 4(e)), and quite sim-
ilar to the cross-section of p300 FL, except for an increased height
value (Table 1), plausibly as a result of antibody binding at the ter-
minal bulge region. This result not only reﬂects the fact that the N-
terminal of p300 FL is located at the terminal bulge region of the
protein, but also conﬁrms that the previously described antibody
(His-Tag mAb/C-terminal speciﬁc antibody) binding interactions
are speciﬁc in nature.
3.3. The p53 binds at the central region of p300 FL
After obtaining an idea about the location of the C-terminal and
N-terminal of p300 FL, we investigated the binding of the tumor
suppressor protein p53 to p300 FL. We chose a p53 mutant2 where
threonine 18 is replaced with the phosphomimetic amino acid, glu-
tamic acid [13], since it has been shown that threonine 18 phosphor-
ylated p53 binds most tightly with p300 [11]. The complex between
p300 FL and p53 mutant were found to be elongated in shape
(Fig. 3(e)) having an average length of 129.5 ± 9.2 nm, which is less
than the length of free p300 FL. This probably suggests that while
forming the complex with p53, the full-length p300 molecule folded
to some extent, as predicted by Teufel et al. that the p300 FL ‘wraps
around p530 for complex formation [12], giving rise to the shorter
length of the complex. The cross-section proﬁle of the p300 FL –
p53 complex indicates that p53 binds at the central region of p300
FL. We have shown earlier in section 3.2 that the C-terminal end
of p300 FL is also centrally located. These observations agree well
to the observation made by Gu et al., who showed that p53 binds
to the C-terminal region of CREB-binding protein (CBP), which shares2 The p53 mutant was characterized by AFM (see Supplementary material). These
molecules were spherical in shape having width distributions 24–26 nm and 34–
36 nm.extensive homology to the p300 FL [6]. The p53 protein is normally a
tetramer and hence contains four activation domains. Recently, a
model has been proposed in which four domains bind to Taz1,
Taz2, IHD and Ibid domains of p300 simultaneously [12]. Although
the present data cannot directly conﬁrm or reject such a hypothesis3,
it is important to note that the presence of N- and C-terminal regions
near the central portion of the prolate ellipsoid suggests that all four
domain could exist spatially close near the central portion of the
molecule and hence capable of binding all four domains simulta-
neously. Interestingly, the bound p53 molecule can also be located
in this region, indirectly supporting the model.
4. Conclusion
In conclusion, p300 FL molecules were found to be nearly pro-
late ellipsoidal in shape, having multiple bulges of different sizes
– distributed throughout the structure, which all together could
represent the different structural domains of p300 FL. We have
identiﬁed the locations of C-terminal and N-terminal regions of
p300 FL at the central part and at the terminal bulge part, respec-
tively, by employing C-terminal speciﬁc and N-terminal speciﬁc
antibody molecules. In addition, we have located the p53 binding
region on p300 FL, which appears to be at the C-terminal region
of p300 FL molecule. Furthermore, the size of the p300 HAT domain
(residues 1284–1517), which is the largest domain of p300 FL, is
such that it appears to be a part of the largest bulge observed in
the AFM topographs. Here, it is tempting to presume that the
non-bulge region, which may represent the rest of the p300 do-
mains, is necessary for most of the protein–protein interactions
in the p300 molecule, and which would further fold back upon a
factor (protein) binding for translating the binding message to
the catalytic (HAT) domain of the p300. The presence of the single
large bulge in our study supports the monomeric nature of p300 FL
as suggested for the p300 HAT domain [7]. Interestingly, our model
also provides a physical understanding of the trans-nature of the
autoacetylation of the p300 [22] where the large bulge part (HAT
domain) can be easily available to the other p300 molecule. Thus,
it appears that the arrangement of the protein domains in p300
is not linear/sequential. The approach taken here could provide
further insight into domain relationships, if more domain-speciﬁc
monoclonal antibodies can be raised. This study may also help to
develop p300 as a model protein molecule to study inter-domain
interaction within a single protein molecule.p300 (see Table 1). From this comparison, we can suggest that it is not the monomeric
p53 that is binding with p300 because in that case it will be a 53 kD protein (p53)
binding with p300 that can’t give rise to a height value similar to that of 150 kD
antibody binding. Hence, it could be either dimeric (i.e., 100 kD) or tetrameric (i.e.,
200 kD) p53 that is binding with p300 FL.
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